Welcome and good morning from our side as well. We are quite pleased with this quarter's performance. It's good to see returns in terms of organic growth and a strong EBITA margin. Let's start with some highlights. As I mentioned, we saw stable order intake growth of 6% overall, with a 1% increase organically. We continued to see strong demand in the medical technology and pharmaceutical sectors as well as in the process industry.
This covers largely the same segments and sectors as in the first quarter. Net sales increased by 5% organically; this growth was 1%, despite it being supported by strong performance in prior periods and additional working days. EBITA margin stood at 14.8%. This is exactly the same as the underlying EBITA margin from last year. Inventory was slightly lower compared to the first quarter of 2024.
Additionally, the pace of acquisitions remained strong. We completed six acquisitions in the second quarter, and 12 in total so far in 2024. The influx of promising acquisition targets remains high. Let's discuss further the order intake and sales. We observed a steady, high demand in order intake and an increased invoicing pace compared to the first quarter, resulting in a record high of 8.5 billion SEK. Both order intake and net sales showed a 1% organic increase compared to the high levels of last year. With additional working days, total order intake and net sales both grew by 6% and 5%, respectively, supported by our strong acquisition pace this year.
Organically, we still experienced some variations between different segments and companies, and I'll elaborate more on this later. In terms of sectors, the medtech and pharmaceutical industries performed well. Specifically, the diabetes sector saw robust performance, both in insulin production in the Danish market and device sales in the Scandinavian and Nordic markets. Additionally, demand was strong in the process industry across a broader scope.
As I've mentioned previously, our companies widely benefit from the green transformation, especially in Scandinavia. However, there are quite a few projects in Western Europe as well. Customer demand in the engineering sector remained stable. The scenario varied more widely geographically, being stronger in the Scandinavian and Nordic areas, but somewhat weaker further south in Europe.
The business climate in the infrastructure and construction sector continued to be subdued. However, there are signs of improvement with more project discussions, as expectations of a better financial climate in the latter half of the year are anticipated to have a positive impact. Nevertheless, the recovery will likely be gradually progressive. The impact is expected to be more significant in 2025 and beyond.
Discussing sales from a geographical perspective, as you can see on the slide here, there was strong development in the Nordics, with particularly higher sales growth in Denmark. Finland displayed slightly lower growth overall, subdued by strong performances last year from major deliveries to pulp and paper customers. As you also know, Finland's base industry typically experiences lower demand early in the cycle, but then rebounds more quickly. Also, when the cycle turns, the business climate generally becomes slightly weaker in central parts of Europe, with the strongest sales development in Germany among the larger markets and weakest in the Benelux Netherlands area; sales for North America and Asia are slightly volatile for us, and the development can fluctuate with single projects and companies.
And this year, we noted more activities and projects, primarily from US customers. If we then look at the EBIT-I margins overall, there is a recovery, which was obviously very good to see. And we weren't really happy with the development in quarter one. And now, we bounced back to the level where we should be at 14.8%, driven by sequentially improved sales.
It's also, as I said, exactly the same level. Yes, the same as last year, excluding the positive influence we had then; compared to last year, the EBIT-A increased by a total of 3%, with -2% organically and +5% from acquisitions organically. The gross margin strengthened slightly also this quarter, but the sales growth did not fully compensate for the increase in expenses. The organic expense growth was, however, below 2%, so we see the impact from better cost management in quarter two compared to quarter one, and I assume this will continue also in H2.
If we look at the different business areas, we can say that half of the company showed sales growth this quarter and three out of five business areas. The strongest development was in Life Science and Technology and System Solutions. The growth in life science was driven by sales of diabetes-related products in the Nordics and production equipment from Novo Nordisk in Denmark, and the positive sales development in Technology and System Solutions came from several customer segments, with the majority of the company showing broad and good sales development also in this business area.
Process, Energy and Water were partly offset by strong results. References to valves, bell's paper for power generation. And then, finally, slightly dampened market climate impacts. The Business area of Industrial and Engineering and Infrastructure and Construction was impacted.
<tr /> So, a little bit more of a dampening situation in the Industrial and Engineering areas. This is versus what we have seen before. Nothing dramatic. And, as we have also commented before,
</tr /> It's good to remember that most of our companies are small to medium size and usually find business opportunities by being entrepreneurial and innovative. If we look at the EBITA margin by business area, I would say it was a solid margin performance, with improvements in three out of five; the development and level in Industrial Engineering and Infrastructure and Construction were held back by the dampened market and organic sales decline. But acquisitions and divestments supported a margin improvement in Infrastructure and Construction. The good margin levels and development in Life Science, Process, Energy, and Water, and Technology and System Solutions were driven by positive organic gross margin development and solid sales growth.
In terms of acquisitions, we have a high pace so far in 2020 with 12 well-managed companies acquired, having combined annual sales of more than SEK 1.5 billion. All business areas have acquired one or more companies, and we have a number of projects in different phases ongoing. So I would guess that we will have, all in all, a good acquisition year. As we have said before, we have the capability to acquire around 20 companies per year. And the conditions continue to be good. I would say going forward here. And, uh, we don't typically measure acquisitions by quarter. It's more accurate to evaluate them over a longer time period. And, uh, when comparing 2023 to 2024 so far, it's important to note that we deliberately extended some processes in 2023. Uh, but nonetheless, there has been a high pace so far this year. And to the right, you can see the EBITA effects from the acquisitions. And, uh, in the first quarter, the effects were relatively modest, around 30 million SEK. Now in the second quarter, we've reached a more typical level of 60 million SEK. And, uh, the acquisitions we concluded in the second quarter had an EBITA margin of about 16%. And, uh, I believe the effects will continue to be positive for the rest of the year. And with that, I invite Patrik to go through the financial details.